Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-11

Clinical Trial Update: Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of bortezomib with high-dose melphalan in multiple myeloma has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bortezomib (bortezomib)
  • Melphalan (Melphalan)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-11